NCT06691308

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

Clinical Study Evaluating the Safety and Efficacy of WL276 CAR-T Cell Therapy in CD276 Positive Recurrent or Progressive Glioblastoma Patients

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Clinical study evaluating the safety and efficacy of WL276 CAR-T cell therapy in CD276 positive recurrent or progressive glioblastoma patients

Detailed description

This study is an open label, single center early exploratory clinical trial of WL276001 CAR-T cell therapy for CD276 positive recurrent or progressive glioblastoma patients. This study used an improved "3+3" experimental design for dose escalation to explore the safety and efficacy of in-situ administration of WL276001 CAR-T cells.

Conditions

• Recurrent or Progressive Glioblastoma

Interventions

Type	Name	Description
COMBINATION_PRODUCT	WL276 CAR-T cells	This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses

Timeline

• Start date: 2024-11-12
• Primary completion: 2027-05-31
• Completion: 2027-05-31
• First posted: 2024-11-15
• Last updated: 2024-11-18